| Name | Title | Contact Details |
|---|
IncludeHealth is a digital health and performance company delivering next-generation musculoskeletal care and training. Offered through a monthly subscription, their platform provides a comprehensive digital suite that pairs HIPAA compliant cloud software with connected equipment, sensors and data to quantify and qualify human performance. This unique pairing provides breakthrough capabilities such as centralized and standardized protocols, outcomes-based data collection, autonomous instruction and documentation, and location agnostic delivery to produce better outcomes with lower costs. The proprietary technology at IncludeHealth has been recognized with 28 international innovation and health awards and is utilized in orthopedics, neuroscience, pediatric care, senior care, government, and general wellness facilities.
Practice Velocity is a Belvidere, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias. We have created a unique platform, ZIO by iRhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.
BDF is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.